Vertex Pharmaceuticals (VRTX) Accumulated Depreciation & Amortization (2016 - 2025)
Historic Accumulated Depreciation & Amortization for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $1.2 billion.
- Vertex Pharmaceuticals' Accumulated Depreciation & Amortization rose 1308.23% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year increase of 1308.23%. This contributed to the annual value of $1.2 billion for FY2025, which is 1308.23% up from last year.
- Per Vertex Pharmaceuticals' latest filing, its Accumulated Depreciation & Amortization stood at $1.2 billion for Q4 2025, which was up 1308.23% from $1.1 billion recorded in Q4 2024.
- In the past 5 years, Vertex Pharmaceuticals' Accumulated Depreciation & Amortization ranged from a high of $1.2 billion in Q4 2025 and a low of $896.0 million during Q4 2021
- Its 5-year average for Accumulated Depreciation & Amortization is $1.1 billion, with a median of $1.1 billion in 2024.
- Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first surged by 1573.06% in 2023, then plummeted by 1043.82% in 2024.
- Over the past 5 years, Vertex Pharmaceuticals' Accumulated Depreciation & Amortization (Quarter) stood at $896.0 million in 2021, then rose by 14.65% to $1.0 billion in 2022, then grew by 15.73% to $1.2 billion in 2023, then fell by 10.44% to $1.1 billion in 2024, then grew by 13.08% to $1.2 billion in 2025.
- Its Accumulated Depreciation & Amortization was $1.2 billion in Q4 2025, compared to $1.1 billion in Q4 2024 and $1.2 billion in Q4 2023.